蜜桃视频

Authenticating with LexisNexis

Try our Advanced Search for more refined results

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. May 10, 2022

    End-Payor State Claims Stick In Generic Drug Price-Fix MDL

    A Pennsylvania federal court denied a dismissal bid Tuesday from drug companies in sprawling multidistrict litigation over alleged generic drug price-fixing, refusing to toss some state claims from end-payors while rejecting arguments that intervening authority should result in the claims being nixed.

  2. April 07, 2022

    Teva Appears Headed For $100M Price-Fixing Payout To AGs

    After last week's $1.45 million settlement with Louisiana's attorney general, a pattern is emerging in Teva's efforts to deal its way out of sprawling price-fixing litigation that could put the generic-drug maker on the hook for about $100 million if it settles with every state enforcer.

  3. March 16, 2022

    Drug Purchasers Seek Blessing Of Sun And Taro Deals

    Generic-drug buyers on Wednesday asked a Pennsylvania federal court to certify a settlement class and preliminarily approve settlements with Sun Pharma and Taro Pharmaceuticals worth a combined $85 million, the first on behalf of any private plaintiff in sprawling multidistrict litigation聽over alleged price-fixing of generic drugs.

  4. March 09, 2022

    Nothing 'Innocuous' In Drugmakers' Dismissal Bid, Court Told

    Generic-drug buyers urged a Pennsylvania federal judge Tuesday not to consider a dismissal bid from pharmaceutical companies more recently added to multidistrict price-fixing litigation, arguing the motion was filed in violation of an agreement to tackle bellwether cases first.

  5. November 05, 2021

    2 Sun Pharma US Units To Pay $85M In Generic Drugs MDL

    Two U.S. subsidiaries of Indian drugmaker Sun Pharma have agreed to shell out a combined $85 million to a proposed class of direct purchaser plaintiffs in sweeping multidistrict litigation over alleged price-fixing of generic drugs, the companies have reportedly disclosed.

  6. June 10, 2021

    Judge Slams Calif. For Discovery Violation In Generics MDL

    A Pennsylvania federal judge overseeing a sweeping multidistrict litigation program over alleged price-fixing of generic drugs expressed frustration during a hearing Thursday as she contemplated sanctioning the California Attorney General's Office over its failure to hand over data it may rely on in building its case.

  7. May 14, 2021

    AGs Say High Court Ruling Doesn't Weaken Drug Price Claims

    State attorneys general on Friday blasted a bid by generic-drug makers to use a recent U.S. Supreme Court ruling as a shield against the prosecutors' price-fixing claims, telling a聽Pennsylvania federal court that the justices' decision doesn't address the relevant law.

  8. May 07, 2021

    Dermatology Case Tapped As Bellwether In Generic Drug MDL

    A Pennsylvania federal judge has selected a case from state enforcers over dermatology treatments to serve as a bellwether in the multidistrict litigation over price-fixing in the generic-drug industry.

  9. May 05, 2021

    Generic-Drug Makers Knock States' Objection To Sanctions

    Generic-drug makers accused of participating in an industrywide price-fixing scheme are urging a Pennsylvania federal court to disregard state enforcers' objections to a special master's recommendation to sanction the California attorney general's office for failing to fulfill discovery obligations in the multidistrict litigation.

  10. April 27, 2021

    AGs Warn Against Sanctioning Calif. In Generics Pricing MDL

    The attorneys general of Pennsylvania, Oregon and Minnesota urged a Pennsylvania federal judge to reject a special master's recommendation to sanction the California Attorney General's Office for failing to fulfill discovery obligations in multidistrict litigation over inflated medication prices, arguing that it has broad implications.